| Interleukin 12: still a promising candidate for tumor immunotherapy? W Lasek, R Zagożdżon, M Jakobisiak Cancer Immunology, Immunotherapy 63, 419-435, 2014 | 532 | 2014 |
| Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer K Marhelava, Z Pilch, M Bajor, A Graczyk-Jarzynka, R Zagozdzon Cancers 11 (11), 1756, 2019 | 116 | 2019 |
| Oxidative stress in kidney diseases: the cause or the consequence? N Krata, R Zagożdżon, B Foroncewicz, K Mucha Archivum immunologiae et therapiae experimentalis 66, 211-220, 2018 | 116 | 2018 |
| Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice W Feleszko, R Zagożdżon, J Gołąb, M Jakobisiak European Journal of Cancer 34 (3), 406-411, 1998 | 109 | 1998 |
| Antitumor effects of interleukin-12 in pre-clinical and early clinical studies J Golab, R Zagozdzon International journal of molecular medicine 3 (5), 537-581, 1999 | 97 | 1999 |
| Potentiation of the anti-tumour effects of Photofrin®-based photodynamic therapy by localized treatment with G-CSF J Goląb, G Wilczyński, R Zagożdżon, T Stoklosa, A Dąbrowska, ... British journal of cancer 82 (8), 1485-1491, 2000 | 88 | 2000 |
| Intrinsic functional potential of NK-cell subsets constrains retargeting driven by chimeric antigen receptors VYS Oei, M Siernicka, A Graczyk-Jarzynka, HJ Hoel, W Yang, D Palacios, ... Cancer immunology research 6 (4), 467-480, 2018 | 83 | 2018 |
| Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer PC O’Leary, M Terrile, M Bajor, P Gaj, BT Hennessy, GB Mills, ... Breast Cancer Research 16, 1-15, 2014 | 63 | 2014 |
| Immunomodulation by anticancer chemotherapy: more is not always better R Zagozdzon, J Golab International journal of oncology 18 (2), 417-424, 2001 | 60 | 2001 |
| Direct stimulation of macrophages by IL-12 and IL-18—a bridge too far? J Gołąb, R Zagożdżon, T Stokłosal, R Kamiński, K Kozar, M Jakóbisiak Immunology letters 72 (3), 153-157, 2000 | 60 | 2000 |
| Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer PC O´ Leary, SA Penny, RT Dolan, CM Kelly, SF Madden, E Rexhepaj, ... BMC cancer 13, 1-13, 2013 | 58 | 2013 |
| Effective chemo‐immunotherapy of L1210 leukemia in vivo using interleukin‐12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin R Zagozdzon, J Gołab, T Stokłosa, A Giermasz, D Nowicka, W Feleszko, ... International journal of cancer 77 (5), 720-727, 1998 | 57 | 1998 |
| Potentiation of the anti‐tumor effect of actinomycin D by tumor necrosis factor α in mice: Correlation between in vitro and in vivo results W Lasek, A Giermasz, K Kuc, A Wańkowicz, W Feleszko, J Golab, ... International journal of cancer 66 (3), 374-379, 1996 | 56 | 1996 |
| Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma A Trzeciecka, S Klossowski, M Bajor, R Zagozdzon, P Gaj, A Muchowicz, ... Oncotarget 7 (2), 1717, 2016 | 55 | 2016 |
| Statins impair glucose uptake in human cells D Nowis, A Malenda, K Furs, B Oleszczak, R Sadowski, J Chlebowska, ... BMJ Open Diabetes Research and Care 2 (1), e000017, 2014 | 54 | 2014 |
| Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents M Bajor, AO Zych, A Graczyk-Jarzynka, A Muchowicz, M Firczuk, ... British Journal of Cancer 119 (7), 873-884, 2018 | 53 | 2018 |
| Carboxyl-Terminal Src Kinase Homologous Kinase Negatively Regulates the Chemokine Receptor CXCR4 through YY1 and Impairs CXCR4/CXCL12 (SDF-1α)–Mediated Breast Cancer Cell Migration BC Lee, TH Lee, R Zagozdzon, S Avraham, A Usheva, HK Avraham Cancer research 65 (7), 2840-2845, 2005 | 52 | 2005 |
| Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice. J Golab, T Stoklosa, A Czajka, A Dabrowska, M Jakobisiak, R Zagozdzon, ... Anticancer research 20 (3A), 1717-1721, 2000 | 51 | 2000 |
| Truncated HER2: implications for HER2-targeted therapeutics R Zagozdzon, WM Gallagher, J Crown Drug discovery today 16 (17-18), 810-816, 2011 | 44 | 2011 |
| Inhibition of autophagy sensitizes cancer cells to Photofrin-based photodynamic therapy A Domagala, J Stachura, M Gabrysiak, A Muchowicz, R Zagozdzon, ... BMC cancer 18, 1-10, 2018 | 43 | 2018 |
